>Marché de la cystite interstitielle en Amérique du Nord, par gravité (légère à modérée et modérée à sévère), type de traitement (médicaments, instillations vésicales, toxine botulique A, stimulation nerveuse et chirurgie ), voie d'administration (orale, parentérale, intravésicale, topique et autres), mode d'achat ( en vente libre et sur ordonnance), type de patient (pédiatrique et adulte), utilisateur final (hôpitaux, cliniques, soins à domicile et autres), canal de distribution (appel d'offres direct, vente au détail et autres) - Tendances et prévisions de l'industrie jusqu'en 2029.
Analyse et taille du marché de la cystite interstitielle en Amérique du Nord
Une forme de douleur vésicale appelée cystite interstitielle (CI) provoque une douleur persistante dans la vessie et le plancher pelvien sans étiologie connue. On parle alors de syndrome d'inconfort pelvien persistant urologique féminin. Les symptômes sont la sensation d'avoir envie d'uriner immédiatement et fréquemment. Une qualité de vie moindre et la dépression sont liées à la CI/SVD. De nombreuses personnes atteintes souffrent également de fibromyalgie et du syndrome du côlon irritable.
Le marché de la cystite interstitielle en Amérique du Nord devrait connaître une croissance du marché au cours de la période de prévision de 2022 à 2029. Data Bridge Market Research analyse que le marché croît avec un TCAC de 10,8 % au cours de la période de prévision de 2022 à 2029 et devrait atteindre 1 123,31 millions USD d'ici 2029.
|
Rapport métrique |
Détails |
|
Période de prévision |
2022 à 2029 |
|
Année de base |
2021 |
|
Années historiques |
2020 (personnalisable jusqu'en 2019-2014) |
|
Unités quantitatives |
Chiffre d'affaires en millions USD |
|
Segments couverts |
Par gravité (légère à modérée et modérée à sévère), type de traitement (médicaments, instillations vésicales, toxine botulique A, stimulation nerveuse et chirurgie ), voie d'administration (orale, parentérale, intravésicale, topique et autres), mode d'achat (en vente libre et sur ordonnance), type de patient (pédiatrique et adulte), utilisateur final (hôpitaux, cliniques, soins à domicile et autres), canal de distribution (appel d'offres direct, vente au détail et autres) |
|
Pays couverts |
États-Unis, Canada et Mexique. |
|
Acteurs du marché couverts |
Alvogen, Janssen Pharmaceuticals, Inc., Sandoz AG, Sun Pharmaceutical Industries Ltd., Accord Healthcare US, Avet Pharmaceuticals Inc., Lannett, Viatris Inc., Pfizer, Inc., Strides Pharma Science Limited, GSK plc. Prestige Consumer Healthcare Inc., Amneal Pharmaceuticals LLC, Zydus Pharmaceuticals, Inc., Apotex Inc., Aurobindo Pharma USA, VistaPharm, Inc., Dr. Reddy's Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Bayer AG et Reckitt Benckiser Group PLC, entre autres. |
Définition du marché
A persistent illness known as interstitial cystitis causes bladder pressure, bladder pain and pelvic pain. Mild discomfort to severe agony is all possible levels of pain. The disorder belongs to a group of illnesses called painful bladder syndrome. Different tests are performed by doctors to diagnose the painful bladder disorder, which include X-rays, urine tests and a bladder wall examination using a cystoscope. It is characterized by pain, pressure, or discomfort perceived to be related to the urinary bladder that lasts more than six months with at least one other urinary symptom, such as frequency or persistent urge. These bladder disorders cause inflammation in the bladder, which is generally called cystitis. Treatment of the disorder depends on the cause of the problem. It may include medication and surgery in severe cases.
Interstitial Cystitis Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
-
INCREASED PREVALENCE OF INTERSTITIAL CYSTITIS (IC)
The disorder known as interstitial cystitis (IC), also known as bladder discomfort syndrome, is chronic or long-lasting and it produces uncomfortable urine symptoms. Individuals with IC may experience varied symptoms. For example, some persons experience little pressure, pain, or discomfort in the pelvic region. Others may battle with severe bladder pain, urinary urgency—the sudden need to urinate—or frequency—the desire to urinate more frequently. One of the main factors influencing the growth rate of the interstitial cystitis market is the increasing prevalence of interstitial cystitis nowadays. Women are particularly affected by this condition. Common side effects include allergies, fibromyalgia and endometriosis. Urinary frequency, urgency and pelvic pain are clinical symptoms of interstitial cystitis, which can occur both during the day and at night.
-
RISE IN HEALTHCARE EXPENDITURE
The cost of healthcare has climbed globally as people's disposable income has increased in different countries. Additionally, government agencies and healthcare providers are taking the initiative by increasing healthcare spending in order to meet population needs.
For instance,
-
As per December 2020, World Health Organization (WHO) report stated that healthcare expenditure was rising in 2018, which was USD 8.3 trillion, which is around 10% of GDP (USD1.080 per citizen) compared to USD 7.6 trillion in 2016. Moreover, global health spending grew by 3.9 percent between 2000 and 2017.
Growing healthcare expenditure is also benefiting further economic growth and healthcare sector growth. It is primarily helpful as it significantly affects the development of better and advanced medical products in the market. Thereby surge in healthcare expenditure is expected to act as a driver for the interstitial cystitis market.
Opportunities
-
IMPROVING HEALTHCARE SYSTEM
Interstitial cystitis or bladder pain syndrome is a chronic pelvic pain syndrome related to the urinary bladder. It is characterized by pain, pressure, or discomfort perceived to be related to the urinary bladder that lasts more than six months with at least one other urinary symptom, such as frequency or persistent urge. Thus, improvement in one or more symptoms of bladder pain can be particularly effective in improving residual urine and bladder hyperextension.
As a result of rising infectious diseases worldwide, it is required to build a better healthcare system for the diagnosis of various infections in underdeveloped regions. Improving healthcare systems in underdeveloped regions can fuel market growth over the forecast period.
These awareness programs helped people understand the correct treatment at an appropriate time. This increasing awareness allows the consumers to select novel treatments as per age and it is efficacy, which enhances the sales of different types of products. Thus, improving a better healthcare system is expected to act as an opportunity for North America interstitial cystitis market growth in the forecasted period.
Restraints/Challenges
However, the barriers to interstitial cystitis treatment techniques and the high cost of the treatment process in some regions may impede the growth of interstitial cystitis treatment hampering the market growth. Additionally, high competition in medical technology industries and long lead time for the overseas qualification can be challenging factors for the growth of the market.
This interstitial cystitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lung cancer surgery market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you to make an informed market decision to achieve market growth.
Recent Development
- In July 2020, UCB and Ferring Pharmaceuticals Inc. announced they had entered into a co-promotion agreement to commercialize the prefilled syringe formulation of CIMZIA used for interstitial cystitis.
- In April 2021, Kyorin Pharmaceutical Co., Ltd., a wholly owned subsidiary of KYORIN Holdings, Inc., launched Interstitial cystitis “Zymso Intravesical Solution 50 %.
North America Interstitial Cystitis Market Scope
Le marché nord-américain de la cystite interstitielle est segmenté en fonction de la gravité, du type de traitement, de la voie d'administration, du mode d'achat, du type de patient, de l'utilisateur final et du canal de distribution. La croissance de ces segments vous aidera à analyser les faibles segments de croissance des industries et à fournir aux utilisateurs un aperçu précieux du marché et des informations sur le marché pour prendre des décisions stratégiques afin d'identifier les principales applications du marché.
Gravité
- Légère à modérée
- Modéré à sévère
Sur la base de la gravité, le marché nord-américain de la cystite interstitielle est segmenté en légère à modérée et modérée à sévère.
Type de traitement
- Médicaments
- Instillation vésicale
- Toxine botulique A
- Stimulation nerveuse
- Chirurgie
Sur la base du type de traitement, le marché nord-américain de la cystite interstitielle est segmenté en médicaments, instillation vésicale, toxine botulique A, stimulation nerveuse et chirurgie.
Voie d'administration
- Oral
- Parentérale
- Intravésicale
- Topique
- Autres
Sur la base de la voie d’administration, le marché nord-américain de la cystite interstitielle est segmenté en voie orale, parentérale, intravésicale, topique et autres.
Mode d'achat
- Sur le comptoir
- Ordonnance
Sur la base du mode d’achat, le marché nord-américain de la cystite interstitielle est segmenté en vente libre et sur ordonnance.
Type de patient
- Pédiatrique
- Adultes
En fonction du type de patient, le marché nord-américain de la cystite interstitielle est segmenté en pédiatrie et en adultes.
Utilisateur final
- Hôpitaux
- Cliniques
- Soins à domicile
- Autres
Sur la base de l’utilisateur final, le marché nord-américain de la cystite interstitielle est segmenté en hôpitaux, cliniques, soins de santé à domicile et autres.
Canal de distribution
- Appel d'offres direct
- Ventes au détail
- Autres
Sur la base des canaux de distribution, le marché nord-américain de la cystite interstitielle est segmenté en appels d'offres directs, ventes au détail et autres.
Analyse/perspectives régionales du marché de la cystite interstitielle
Le marché de la cystite interstitielle est analysé et des informations et tendances sur la taille du marché sont fournies par pays, gravité, type de traitement, voie d’administration, mode d’achat, type de patient, utilisateur final et canal de distribution, comme référencé ci-dessus.
Les États-Unis dominent le marché nord-américain de la cystite interstitielle en termes de part de marché et de chiffre d'affaires et continueront de renforcer leur domination au cours de la période de prévision. Cela est dû au besoin croissant de vérification et de validation des processus de traitement de la cystite interstitielle dans la région, et au développement rapide de la recherche qui stimule le marché
La section pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données, tels que les ventes de produits neufs et de remplacement, la démographie des pays, l'épidémiologie des maladies et les tarifs d'importation et d'exportation, sont quelques-uns des principaux indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la forte concurrence des marques locales et nationales et l'impact des canaux de vente sont pris en compte lors de l'analyse prévisionnelle des données nationales.
Analyse du paysage concurrentiel et des parts de marché de la cystite interstitielle
Le paysage concurrentiel du marché de la cystite interstitielle fournit des détails par concurrents. Les détails comprennent un aperçu de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit et la domination des applications. Les points de données ci-dessus ne concernent que l'accent mis par les entreprises sur le marché de la cystite interstitielle.
Français Certains des principaux acteurs opérant sur le marché de la cystite interstitielle sont Alvogen, Janssen Pharmaceuticals, Inc., Sandoz AG, Sun Pharmaceutical Industries Ltd., Accord Healthcare US, .Avet Pharmaceuticals Inc., Lannett, Viatris Inc., Pfizer, Inc., Strides Pharma Science Limited, GSK plc. Prestige Consumer Healthcare Inc., Amneal Pharmaceuticals LLC, Zydus Pharmaceuticals, Inc., Apotex Inc., Aurobindo Pharma USA, VistaPharm, Inc., Dr. Reddy's Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Bayer AG et Reckitt Benckiser Group PLC, entre autres.
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. Les données du marché sont analysées et estimées à l'aide de modèles statistiques et cohérents du marché. En outre, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. La principale méthodologie de recherche utilisée par l'équipe de recherche DBMR est la triangulation des données, qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). En dehors de cela, les modèles de données comprennent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des parts de marché des entreprises, les normes de mesure, l'Amérique du Nord par rapport aux régions et l'analyse des parts des fournisseurs. Veuillez demander un appel d'analyste en cas de demande de renseignements supplémentaires.
SKU-
Accédez en ligne au rapport sur le premier cloud mondial de veille économique
- Tableau de bord d'analyse de données interactif
- Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
- Accès d'analyste de recherche pour la personnalisation et les requêtes
- Analyse de la concurrence avec tableau de bord interactif
- Dernières actualités, mises à jour et analyse des tendances
- Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Table des matières
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA INTERSTITIAL CYSTITIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
4.3 PIPELINE ANALYSIS FOR INTERSTITIAL CYSTITIS TREATMENT MARKET
4.4 EPIDEMIOLOGY
5 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: REGULATIONS
5.1 FOOD AND DRUG ADMINISTRATION (FDA) GUIDELINES
5.2 EUROPEAN MEDICINES AGENCY (EMA) GUIDELINES
5.3 JAPAN REGULATORY GUIDANCE
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASED PREVALENCE OF INTERSTITIAL CYSTITIS (IC)
6.1.2 RISE IN HEALTHCARE EXPENDITURE
6.1.3 STRATEGIC INITIATIVES OF KEY PLAYERS
6.1.4 INCREASE IN R&D EFFORTS IN THE HEALTHCARE INDUSTRY
6.1.5 RISING DISEASE MANAGEMENT PROGRAMS
6.2 RESTRAINTS
6.2.1 HIGH COST OF TREATMENT OF INTERSTITIAL CYSTITIS
6.2.2 LACK OF AWARENESS ABOUT BLADDER DISORDERS-RELATED PROBLEMS
6.2.3 DEARTH OF SKILLED PROFESSIONALS
6.3 OPPORTUNITIES
6.3.1 FAVORABLE REIMBURSEMENT SCENARIO
6.3.2 INCREASE IN DRUG APPROVALS AND LAUNCHES
6.3.3 IMPROVING HEALTHCARE SYSTEM
6.3.4 COMBINATION OF DIFFERENT TARGET THERAPIES
6.4 CHALLENGES
6.4.1 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL
6.4.2 PATENT EXPIRY OF DRUGS
7 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY
7.1 OVERVIEW
7.2 MILD TO MODERATE
7.3 MODERATE TO SEVERE
8 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE
8.1 OVERVIEW
8.2 MEDICATIONS
8.2.1 ANALGESICS
8.2.1.1 NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
8.2.1.1.1 IBUPROFEN
8.2.1.1.2 NAPROXEN
8.2.1.1.3 OTHERS
8.2.1.2 ACETAMINOPHEN
8.2.1.3 NON-NARCOTIC PAIN MEDICATION
8.2.1.3.1 METHENAMINE
8.2.1.3.2 PHENAZOPYRIDINE
8.2.1.3.3 OTHERS
8.2.1.4 NARCOTIC PAIN MEDICATION
8.2.1.4.1 CODEINE
8.2.1.4.2 HYDROCODONE
8.2.1.4.3 OXYCODONE
8.2.1.4.4 OXYMORPHONE
8.2.1.4.5 MORPHINE
8.2.1.4.6 HYDROMORPHONE
8.2.1.4.7 METHADONE
8.2.1.4.8 OTHERS
8.2.2 ANTIHISTAMINES
8.2.2.1 LORATADINE
8.2.2.2 HYDROXYZINE
8.2.2.3 OTHERS
8.2.3 TRICYCLIC ANTIDEPRESSANTS
8.2.3.1 AMITRIPTYLINE
8.2.3.2 IMIPRAMINE
8.2.3.3 OTHERS
8.2.4 IMMUNOSUPPRESSANTS
8.2.4.1 CYCLOSPORINE
8.2.4.2 MYCOPHENOLATE
8.2.4.3 OTHERS
8.2.5 PENTOSAN POLYSULFATE SODIUM
8.2.6 OTHERS
8.2.6.1 ALPHA BLOCKERS
8.2.6.1.1 DOXAZOSIN
8.2.6.1.2 TERAZOSIN
8.2.6.1.3 TAMSULOSIN
8.2.6.1.4 OTHERS
8.2.6.2 AMPHETAMINES
8.2.6.3 LEUKOTRIENE INHIBITORS
8.2.6.3.1 MONTELUKAST
8.2.6.3.2 ZAFIRLUKAST
8.2.6.3.3 OTHERS
8.2.6.4 OTHERS
8.3 BLADDER INSTILLATIONS
8.3.1 DIMETHYL SULFOXIDE
8.3.2 HEPARIN
8.3.3 OTHERS
8.4 BOTULINUM TOXIN A
8.5 SURGERY
8.5.1 FULGURATION
8.5.2 RESECTION
8.5.3 BLADDER AUGMENTATION
8.6 NERVE STIMULATIONS
9 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 ORAL
9.2.1 TABLETS
9.2.1.1 EXTENDED RELEASE
9.2.1.2 IMMEDIATE RELEASE
9.2.2 CAPSULES
9.2.3 OTHERS
9.3 PARENTERAL
9.4 INTRAVESICAL
9.5 TOPICAL
9.6 OTHERS
10 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE
10.1 OVERVIEW
10.2 OVER THE COUNTER
10.3 PRESCRIPTION
11 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE
11.1 OVERVIEW
11.2 ADULTS
11.3 PEDIATRIC
12 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITALS
12.3 CLINICS
12.4 HOME HEALTHCARE
12.5 OTHERS
13 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 RETAIL SALES
13.3.1 PHARMACY STORES
13.3.2 ONLINE RETAIL CHANNEL
13.3.3 OTHERS
13.4 OTHERS
14 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY GEOGRAPHY
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 CANADA
14.1.3 MEXICO
15 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 TEVA PHARMACEUTICALS INDUSTRIES LTD.
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 PRODUCT PORTFOLIO
17.1.4 RECENT DEVELOPMENTS
17.2 SANDOZ AG (A SUBSIDIARY OF NOVARTIS AG)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 HIKMA PHARMACEUTICALS PLC
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 DR. REDDY'S LABORATORIES LTD
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 BAYER AG
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 AMNEAL PHARMACEUTICAL LLC.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENTS
17.7 APOTEX
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENT
17.8 AUROBINDO PHARMA USA
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 AVET PHARMACEUTICALS INC.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 ALVOGEN
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 10.3RECENT DEVELOPMENT
17.11 ACCORD-UK LTD
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 11.3RECENT DEVELOPMENT
17.12 GLAXOSMITHKLINE PLC
17.12.1 COMPANY SNAPSHOT
17.12.2 12.2REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 JOHNSON & JOHNSON SERVICES, INC.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 LANNETT
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 PRESTIGE CONSUMER HEALTHCARE
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENTS
17.16 PFIZER INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 RECKITT BENCKISER GROUP PLC.
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
17.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 STRIDES PHARMA SCIENCE LIMITED.
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENT
17.2 VIATRIS INC.
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.21 VISTA PHARM INC.
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENTS
17.22 ZYDUS PHARMACEUTICALS INC.,
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
Liste des tableaux
TABLE 1 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 2 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA MILD TO MODERATE IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA MODERATE TO SEVERE IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 NORTH AMERICA BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 NORTH AMERICA BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA BOTULINUM TOXIN A IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 NORTH AMERICA NERVE STIMULATIONS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA ORAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA PARENTERAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 NORTH AMERICA INTRAVESICAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA TOPICAL IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA OVER THE COUNTER IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA PRESCRIPTION IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA ADULTS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA PEDIATRIC IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA HOSPITALS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA CLINICS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA HOME HEALTHCARE IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 43 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 44 NORTH AMERICA DIRECT TENDER IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 45 NORTH AMERICA RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 46 NORTH AMERICA RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 47 NORTH AMERICA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 48 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 49 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 50 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 51 NORTH AMERICA MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 NORTH AMERICA ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 NORTH AMERICA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 NORTH AMERICA NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 NORTH AMERICA NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 NORTH AMERICA ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 57 NORTH AMERICA IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 58 NORTH AMERICA TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 NORTH AMERICA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 NORTH AMERICA ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 NORTH AMERICA LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 NORTH AMERICA BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 NORTH AMERICA SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 65 NORTH AMERICA ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 66 NORTH AMERICA TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 67 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 68 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 69 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 NORTH AMERICA RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 U.S. INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 73 U.S. INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 74 U.S. MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 U.S. ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 U.S. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 U.S. NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 U.S. NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 U.S. ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 U.S. IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 U.S. TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 U.S. OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 83 U.S. ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 84 U.S. LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 U.S. BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 U.S. SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 U.S. INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 88 U.S. ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 89 U.S. TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 90 U.S. INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 91 U.S. INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 92 U.S. INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 93 U.S. INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 94 U.S. RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 CANADA INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 96 CANADA INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 97 CANADA MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 CANADA ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 CANADA NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 CANADA NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 CANADA NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 CANADA ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 CANADA IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 CANADA TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 CANADA OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 106 CANADA ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 CANADA LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 CANADA BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 CANADA SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 CANADA INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 111 CANADA ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 112 CANADA TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 113 CANADA INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 114 CANADA INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 115 CANADA INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 116 CANADA INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 117 CANADA RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 118 MEXICO INTERSTITIAL CYSTITIS MARKET, BY SEVERITY, 2020-2029 (USD MILLION)
TABLE 119 MEXICO INTERSTITIAL CYSTITIS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)
TABLE 120 MEXICO MEDICATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 MEXICO ANALGESICS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 122 MEXICO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 123 MEXICO NON-NARCOTIC PAIN MEDICATION IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 MEXICO NARCOTIC PAIN MEDICINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 MEXICO ANTIHISTAMINES IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 126 MEXICO IMMUNOSUPPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 127 MEXICO TRICYCLIC ANTIDEPRESSANTS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 MEXICO OTHERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 MEXICO ALPHA BLOCKERS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 MEXICO LEUKOTRIENE INHIBITORS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 MEXICO BLADDER INSTILLATIONS IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 132 MEXICO SURGERY IN INTERSTITIAL CYSTITIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 MEXICO INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 134 MEXICO ORAL IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 135 MEXICO TABLETS IN INTERSTITIAL CYSTITIS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 136 MEXICO INTERSTITIAL CYSTITIS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 137 MEXICO INTERSTITIAL CYSTITIS MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 138 MEXICO INTERSTITIAL CYSTITIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 139 MEXICO INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 140 MEXICO RETAIL SALES IN INTERSTITIAL CYSTITIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
Liste des figures
FIGURE 1 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA BLADDER DISORDERS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: SEGMENTATION
FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF INTERSTITIAL CYSTITIS IS EXPECTED TO DRIVE THE NORTH AMERICA INTERSTITIAL CYSTITIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 MILD TO MODERATE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA INTERSTITIAL CYSTITIS MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA INTERSTITIAL CYSTITIS MARKET
FIGURE 14 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2021
FIGURE 15 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, 2022-2029 (USD MILLION)
FIGURE 16 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, CAGR (2022-2029)
FIGURE 17 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 18 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2021
FIGURE 19 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 23 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 26 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2021
FIGURE 27 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 30 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2021
FIGURE 31 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION)
FIGURE 32 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 33 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 34 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, 2021
FIGURE 35 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 36 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 37 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 39 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 40 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 41 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 42 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: SNAPSHOT (2021)
FIGURE 43 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021)
FIGURE 44 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 45 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 46 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: BY SEVERITY (2022-2029)
FIGURE 47 NORTH AMERICA INTERSTITIAL CYSTITIS MARKET: COMPANY SHARE 2021 (%)
Méthodologie de recherche
La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.
La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.
Personnalisation disponible
Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.
